Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma

Journal of Hepatology

Volumn 51, Issue 2, 2009, Pages 315-321

  Yoshiji, Hitoshi ^a   Noguchi, Ryuichi ^a   Toyohara, Masahisa ^a   Ikenaka, Yasuhide ^a   Kitade, Mitsuteru ^a   Kaji, Kosuke ^a   Yamazaki, Masaharu ^a   Yamao, Junichi ^a   Mitoro, Akira ^a   Sawai, Masayoshi ^a   Yoshida, Motoyuki ^a   Fujimoto, Masao ^a   Tsujimoto, Tatsuhiro ^a   Kawaratani, Hideto ^a   Uemura, Masahito ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Angiotensin converting enzyme inhibitor; Hepatocellular carcinoma; Vascular endothelial growth factor; Vitamin K2

Indexed keywords

ANTINEOPLASTIC AGENT; MENATETRENONE; PERINDOPRIL; VASCULOTROPIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; FARNOQUINONE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; BLOOD; CATHETER ABLATION; DRUG COMBINATION; LIVER TUMOR; MIDDLE AGED; SURVIVAL RATE; TUMOR RECURRENCE; VASCULARIZATION;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PERINDOPRIL; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITAMIN K 2;

EID: 67649158636     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.04.011     Document Type: Article

References (38)

1. Llovet J.M., and Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48 (2008) S20-S37
2. Ikeda K., Arase Y., Saitoh S., Kobayashi M., Suzuki Y., Suzuki F., et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32 (2000) 228-232
3. Nishiguchi S., Shiomi S., Nakatani S., Takeda T., Fukuda K., Tamori A., et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 357 (2001) 196-197
4. Kudo M., Sakaguchi Y., Chung H., Hatanaka K., Hagiwara S., Ishikawa E., et al. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology 72 (2007) 132-138
5. Shiratori Y., Shiina S., Teratani T., Imamura M., Obi S., Sato S., et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138 (2003) 299-306
6. Carmeliet P. Angiogenesis in health and disease. Nat Med 9 (2003) 653-660
7. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
8. Saaristo A., Karpanen T., and Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 19 (2000) 6122-6129
9. Yoshiji H., Kuriyama S., Hicklin D.J., Huber J., Yoshii J., Miyamoto Y., et al. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 30 (1999) 1179-1186
10. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Yanase K., et al. Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development. J Hepatol 41 (2004) 97-103
11. Yoshiji H., Kuriyama S., Yoshii J., Yamazaki M., Kikukawa M., Tsujinoue H., et al. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 28 (1998) 1489-1496
12. Li C.Y., Shan S., Huang Q., Braun R.D., Lanzen J., Hu K., et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92 (2000) 143-147
13. Bergers G., Javaherian K., Lo K.M., Folkman J., and Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284 (1999) 808-812
14. Brandvold K.A., Neiman P., and Ruddell A. Angiogenesis is an early event in the generation of myc-induced lymphomas. Oncogene 19 (2000) 2780-2785
15. Bolontrade M.F., Stern M.C., Binder R.L., Zenklusen J.C., Gimenez-Conti I.B., and Conti C.J. Angiogenesis is an early event in the development of chemically induced skin tumors. Carcinogenesis 19 (1998) 2107-2113
16. Frachon S., Gouysse G., Dumorti J., Couvelard A., Nejjari M., Mion F., et al. Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study. J Hepatol 34 (2001) 850-857
17. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Hicklin D.J., et al. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 39 (2004) 1517-1524
18. Kerbel R.S. Tumor angiogenesis. N Engl J Med 358 (2008) 2039-2049
19. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
20. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
21. Eskens F.A., and Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 42 (2006) 3127-3139
22. Verheul H.M., and Pinedo H.M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7 (2007) 475-485
23. Berenson A. A cancer drug shows promise, at a price that many can't pay. The New York Times 15 (2006) A1 C2
24. Yoshiji H., Kuriyama S., Noguchi R., Yoshii J., Ikenaka Y., Yanase K., et al. Combination of vitamin K(2) and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J Hepatol 42 (2005) 687-693
25. Yoshiji H., Noguchi R., Yamazaki M., Ikenaka Y., Sawai M., Ishikawa M., et al. Combined treatment of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates hepatic dysplastic nodule in a patient with liver cirrhosis. World J Gastroenterol 13 (2007) 3259-3261
26. Habu D., Shiomi S., Tamori A., Takeda T., Tanaka T., Kubo S., et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 292 (2004) 358-361
27. Mizuta T., Ozaki I., Eguchi Y., Yasutake T., Kawazoe S., Fujimoto K., et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 106 (2006) 867-872
28. Kokudo N., and Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol 44 (2009) 119-121
29. Makuuchi M., Kokudo N., Arii S., Futagawa S., Kaneko S., Kawasaki S., et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 38 (2008) 37-51
30. Okita K. Management of hepatocellular carcinoma in Japan. J Gastroenterol 41 (2006) 100-106
31. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 69 (2005) 11-16
32. Kerbel R.S., and Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4 (2004) 423-436
33. Davis D.W., Inoue K., Dinney C.P., Hicklin D.J., Abbruzzese J.L., and McConkey D.J. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Cancer Res 64 (2004) 4601-4610
34. Dorrell M.I., Aguilar E., Scheppke L., Barnett F.H., and Friedlander M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci USA 104 (2007) 967-972
35. Yoshiji H., Kuriyama S., Kawata M., Yoshii J., Ikenaka Y., Noguchi R., et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 7 (2001) 1073-1078
36. Moriwaki H., Yasuda I., Shiratori Y., Uematsu T., Okuno M., and Muto Y. Deletion of serum lectin-reactive alpha-fetoprotein by acyclic retinoid: a potent biomarker in the chemoprevention of second primary hepatoma. Clin Cancer Res 3 (1997) 727-731
37. Shiraki K., Takase K., Tameda Y., Hamada M., Kosaka Y., and Nakano T. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 22 (1995) 802-807
38. Corradini S.G., Morini S., Liguori F., Carotti S., Muda A.O., Burza M.A., et al. Differential vascular endothelial growth factor A protein expression between small hepatocellular carcinoma and cirrhosis correlates with serum vascular endothelial growth factor A and alpha-fetoprotein. Liver Int 29 (2009) 103-112